Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269175 | 0.87 | MAPT (0.39) | ALDH1A1CNR1KMT2ACYP3A4LMNA | |
| SCHEMBL7687237 | 0.85 | CNR1 (0.43) | ALDH1A1CNR1CYP3A4CPA1 | |
| SCHEMBL7684336 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CYP3A4GAACPA1 | |
| SCHEMBL121043 | 0.84 | PSEN1 (0.40) | ALDH1A1CNR1LMNA | |
| SCHEMBL7686449 | 0.84 | CYP2C19 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL6487215 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CNR1CYP3A4GAALMNA | |
| SCHEMBL6489372 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ACYP3A4CPA1 | |
| SCHEMBL6477248 | 0.84 | CYP2C9 (0.45) | ALDH1A1KMT2ACYP3A4LMNACPA1 | |
| SCHEMBL6492632 | 0.84 | ALDH1A1 (0.40) | ALDH1A1CNR1CYP3A4CPA1 | |
| SCHEMBL13525416 | 0.83 | CNR1 (0.42) | ALDH1A1CNR1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | ALDH1A1 685/4885CNR1 288/4885MEN1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.